Richard E Showalter

Title: Richard E Showalter: Innovator in Protein Engineering

Introduction

Richard E Showalter is a notable inventor based in Lakeside, CA (US). He has made significant contributions to the field of protein engineering, particularly in the study of vascular endothelial growth factor receptor 2 (VEGFR2/KDR). With a total of 5 patents to his name, Showalter's work has implications for therapeutic advancements in various disease conditions.

Latest Patents

One of his latest patents involves modifications of the VEGF receptor-2 protein and methods of use. A 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of VEGFR2/KDR has been determined in an unliganded, phosphorylated state. This protein construct contains a modified catalytic linker and exhibits comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, allowing complete crystallization of the protein for characterization by X-ray crystallography. The invention further discloses the use of the X-ray crystallographic data for the identification and construction of potential therapeutic compounds for treating various disease conditions.

Career Highlights

Richard E Showalter is currently associated with Agouron Pharmaceuticals, Inc., where he continues to advance his research in protein engineering. His work has been instrumental in understanding the mechanisms of angiogenesis and developing therapeutic strategies.

Collaborations

Showalter has collaborated with notable colleagues, including Camran V Parast and Barbara Mroczkowski, contributing to a dynamic research environment that fosters innovation.

Conclusion

Richard E Showalter's contributions to protein engineering and his innovative patents highlight his role as a key figure in the field. His work not only enhances our understanding of critical biological processes but also paves the way for new therapeutic approaches.